Latest Asx Continuous Disclosure News

Invion Limited has affirmed its compliance with ASX disclosure rules following the US FDA’s granting of Orphan Drug Designation for its anal cancer treatment candidate INV043. The company detailed the timing and verification process behind its announcement.

James Hardie Industries confirms its Q1 FY26 earnings met market expectations despite a challenging North American housing market, while revising its FY26 guidance following the AZEK acquisition.

Kaili Resources has responded to ASX inquiries following volatile trading, confirming imminent rare earth element drilling in South Australia and revealing detailed shareholder data.

Kaili Resources has responded to an ASX price query following a dramatic rise in its share price, denying any undisclosed material information and confirming full compliance with ASX listing rules.

Vital Metals Limited has clarified the recent spike in its share price and trading volume, attributing it to a confidential capital raise and a positive scoping study amid a broader rare earths sector rally.

Xamble Group Limited has clarified that its recent share price surge is linked to a newly announced renounceable rights issue, dismissing speculation of undisclosed information.

AGL Energy has clarified that its FY25 underlying earnings aligned with market forecasts and published guidance, dismissing any material surprises in its financial results. The company also addressed statutory profit volatility and confirmed compliance with ASX disclosure rules.

ActivePort Group has confirmed the mutual termination of its loan facility with Radian Arc and the lapse of a key licensing Term Sheet, clarifying its compliance with ASX disclosure rules.

Baby Bunting Group confirms its FY25 financial results align with prior guidance and analyst expectations, addressing ASX queries on disclosure timing amid notable share price movements.

Kaili Resources has officially confirmed a change of control with Mr Jianzhong Yang now holding over 60% of shares, alongside a significant board reshuffle. The company remains focused on advancing its rare earth elements exploration in South Australia.

Invion Limited has disclosed that the US FDA granted Orphan Drug Designation for its lead cancer drug candidate INV043, explaining recent unusual trading activity in its shares. The company confirmed it was unaware of the FDA decision prior to its public release and has now complied with continuous disclosure rules.

Ausmon Resources has addressed a recent spike in its share price and trading volume, attributing the market interest to prior drilling assay results for rare earth elements in South Australia.